5 Hrs
Source:
المشهد العربي
AstraZeneca Shares Drop Sharpest Since 2020
The British pharmaceutical company's AstraZeneca stock experienced its biggest daily loss since March 2020, following the failure of the drug "Waynewa" to achieve desired results in a clinical trial for treating a rare heart disease. The share price dropped by 9.5% to reach £129 ($172.9), after the study, which lasted 140 weeks and involved 1,432 patients, showed it was unable to reduce the mortality rates associated with the disease. Although there was limited benefit for a specific group of patients, the results did not meet expectations for drug approval, raising concerns about the impact of the failure on investor confidence in the company's specialized pharmaceutical portfolio. The company is expected to review its next steps to bolster its research efforts and accelerate the development of more successful treatment pathways.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)